Advertisement

Topics

Ferrer Group Inc. Company Profile

22:49 EST 13th February 2016 | BioPortfolio

Ferrer Grupo offers products of a high scientific standard, according to client needs, together with health training programmes which provide up-to-date information on the constant improvements in the fields of medicine and pharmacology, and maintain direct contact with health professionals, patients and the general public.

Location

Edifici L'illaDiagonal, 549 5a planta
Barcelona
E-08029
Spain

Contact

Phone: 34 93 600 37 00
Fax: 34 93 490 70 78
Email: medicaldepartment@ferrergrupo.com


News Articles [227 Associated News Articles listed on BioPortfolio]

Cipher Pharmaceuticals Announces Successful Completion of Second Phase 3 Study for Ozenoxacin

Cipher Pharmaceuticals Inc. announced that Ferrer International SA ("Ferrer") successfully completed the second phase 3 clinical trial for Ozenoxacin, a topical treatment for adult and paediatric pati...

Cipher Pharmaceuticals Announces Successful Completion of Second Phase III for Ozenoxacin

MISSISSAUGA, ON, July 30, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that Ferrer International SA ("Ferrer") successfully completed the...

Ferrer successfully completes second phase III clinical trial in adult and paediatric patients with impetigo for antibacterial Ozenoxacin

Ferrer announces that it has successfully completed a second phase III clinical trial in adult and paediatric patients aged two months and older with impetigo, utilizing Ozenoxacin 1% cream as a topic...

Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin

FAIRFIELD, N.J., July 30, 2015 /PRNewswire/ -- Medimetriks Pharmaceuticals, Inc. announced today that its licensor, Ferrer, completed the second Phase III clinical study for Ozenoxacin, a no...

Cipher Pharmaceuticals reports second Phase 3 trial for Ozenoxacin

Cipher expects to submit Ozenoxacin for regulatory approval in Canada in the first quarter of 2016 Mississauga, ON – Ferrer International SA has successfully completed the second Phase 3 clinica...

Boeing und Airbus Group vs. Kuoni und TUI AG - kommentierter KW 43 Peer Group Watch Luftfahrt & Reise

In der Wochensicht ist vorne: Boeing 6,61% vor Airbus Group 5,53%, Flughafen Wien 4,44%, FACC 4,26%, Fraport 3,48%, Thomas Cook Group 2,91%, Lufthansa 2,24%, Air Berlin 2,14%, TUI AG 2,06% und Kuon...

BioNeutral Group, Inc. (BONU) - Financial and Strategic SWOT Analysis Review

Recently added to the BioPortfolio report store, BioNeutral Group, Inc. (BONU) - Financial and Strategic SWOT Analysis Review is a new report from GlobalData published on 2015-09-11. This 25-page rep...

Lufthansa und Kuoni vs. Boeing und Airbus Group - kommentierter KW 1 Peer Group Watch Luftfahrt & Reise

In der Wochensicht ist vorne: Lufthansa 2,44% vor Kuoni 0,54%, TUI AG -0,98%, Thomas Cook Group -1,65%, Air Berlin -1,75%, FACC -2,69%, Flughafen Wien -4,68%, Fraport -4,92%, Airbus Group -6,96% un...

PubMed Articles [2407 Associated PubMed Articles listed on BioPortfolio]

The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.

During the last decade, there has been a tremendous effort to develop different cardiovascular polypills in response to the upsurge in global cardiovascular disease worldwide. The pharmacological deve...

I won't tell: Young children show loyalty to their group by keeping group secrets.

Group loyalty is highly valued. However, little is known about young children's loyal behavior. This study tested whether 4- and 5-year-olds (N=96) remain loyal to their group even when betraying it w...

"Echocardiographic abnormalities in patients with COPD at their first hospital admission." Xavier Freixa, Karina Portillo, Carles Paré, Judith Garcia-Aymerich, Federico P. Gomez, Marta Benet, Josep Roca, Eva Farrero, Jaume Ferrer, Carlos Fernandez-Palomeque, Josep M. Antó and Joan Albert Barberà, on behalf of the PAC-COPD Study Investigators. Eur Respir J 2013; 41: 784-791.

Three new species of Macrelmis Motschulsky (Coleoptera: Elmidae: Elminae) from Southeastern Brazil with new definition of species groups to the genus.

Three new species of Macrelmis Motschulsky, 1859 are described and illustrated based on adult males from Rio de Janeiro, Minas Gerais and São Paulo states (southeastern Brazil). A new species groups ...

Activation of Two Sequential H-transfers in the Thymidylate Synthase Catalyzed Reaction.

Thymidylate synthase (TSase) catalyzes the de novo biosynthesis of thymidylate, a precursor for DNA, and is thus an important target for chemotherapeutics and antibiotics. Two sequential C-H bond clea...

Clinical Trials [2032 Associated Clinical Trials listed on BioPortfolio]

Does Cognitive Rehabilitation Demonstrate Benefits in the Group Setting With People Whom Have Experienced Brain Injury?

The purpose of this study is to determine whether there is benefit from providing cognitive rehabilitation in the group setting. Several standardized tools will be used to measure progres...

Short Term Group Therapy for OCD

Assessing OCD before and after group therapy

Early Group Based Parental Support Within Child Health Service - Group Leadership

All parents in Sweden are offered group based parental support within Child Health Service (CHS) but only 40% participate. Nurses feel insecure in their group leadership and express a need...

Group Yoga Therapy at a College Counseling Center

Clients of the student counseling center at Oklahoma State University who are interested in participating in the study will be randomly assigned to a traditional process group, a yoga clas...

Incision Pain and Uterine Contraction Pain After Cesarean Section

This study aims to compare the pain degree between primary cesarean section and repeated cesarean section, and investigate the role of flurbiprofen axetil in postoperative analgesia, so as...

Companies [1521 Associated Companies listed on BioPortfolio]

Ferrer Group Inc.

Ferrer Grupo offers products of a high scientific standard, according to client needs, together with health training programmes which provide up-to-date information on the constant improvements in the...

Ferrer Freeman & Company, LLC

Ferrer Freeman & Company, LLC, is a private equity firm located in Greenwich, CT focuses exclusively on growth capital investments in the healthcare industry. Since its founding i...

DiaGenic ASA & Ferrer inCode

DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for ...

W2 Group, Inc.

W2 Group is a global marketing services ecosystem that helps CMOs in their new role as builders of communities and content aggregators. W2 Group companies, including Digital ...

PharmEvo (Pvt.) Ltd.

PharmEvo is backed by a reputable corporate group with a history of successful business ventures spread over 30 years. The group made its debut in 1971, with the sales and marketing of prestigious bra...

More Information about "Ferrer Group Inc." on BioPortfolio

We have published hundreds of Ferrer Group Inc. news stories on BioPortfolio along with dozens of Ferrer Group Inc. Clinical Trials and PubMed Articles about Ferrer Group Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ferrer Group Inc. Companies in our database. You can also find out about relevant Ferrer Group Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record